The primary objectives of this analysis were to examine the effects of early posttransplantation (10 wk) serum levels of osteoprotegerin (OPG), mannose-binding lectin (MBL), and MBL-associated serine proteases (MASP; MASP-2 and MASP-3) on long-term (8-yr) patient survival, graft survival, and cardiovascular (CV) death. During a period of 16 mo (1995 to 1996), a total of 173 consecutive renal transplant recipients without diabetes before transplantation were included in a prospective study that was designed to address the impact of metabolic CV risk factors on survival and CV end points. Baseline sera from 172 patients were available for analysis. Follow-up data until January 1, 2004, were obtained from a national renal registry. Patients with high (fourth quartile) serum levels of OPG had significantly higher all-cause mortality (hazard ratio [HR] 6.3; 95% confidence interval [CI] 3.3 to 11.8; P < 0.001) and CV death (HR 10.8; 95% CI 3.8 to 30.4; P < 0.001) than patients with lower OPG concentrations. After multiple Cox regression analysis, high serum levels of OPG remained an independent predictor of all-cause mortality (HR 6.0; 95% CI 3.1 to 11.6, P < 0.001) and CV death (HR 8.2; 95% CI 2.5 to 26.4; P < 0.001). Multiple linear regression analysis revealed that age, creatinine clearance, and high-sensitivity C-reactive protein all were independently associated with OPG (R 2 ‫؍‬ 0.42). No significant association between OPG and death-censored graft loss was revealed. Serum levels of MBL, MASP-2, and MASP-3 were not significantly associated with patient survival, CV death, or graft loss. Early measured posttransplantation serum OPG is a highly significant independent predictor of death from any cause or CV death in white renal transplant recipients.
I t generally is accepted that cardiovascular disease (CVD)
is the major cause of death and graft loss in renal transplant recipients (RTR) (1) (2) (3) . However, widely known risk factors such as hypertension, dyslipidemia, and diabetes cannot explain completely the high incidence of CVD in these patients.
In recent years, a number of inflammatory markers and cytokines, including C-reactive protein (CRP), have been associated with CVD. A few studies have addressed this topic in RTR and demonstrated that CRP may be associated with allcause mortality (4, 5) and atherosclerotic events (6) . The possible long-term injurious or beneficial effects of the recently discovered serum proteins osteoprotegerin (OPG) and mannose-binding lectin (MBL) on death and CVD in RTR, however, have not been described in large-scale prospective studies.
OPG is a member of the TNF receptor superfamily that can function as a soluble decoy receptor by binding receptor activator of NF-B ligand (RANKL), thereby competitively inhibiting interaction between RANKL and its receptor RANK. OPG is produced by many cell types, including osteoblasts and various cells of the vasculature, and was identified recently as a risk factor for CVD and vascular mortality (7) (8) (9) . In addition, it has been demonstrated that increased serum OPG levels are associated with increased coronary artery and aorta calcification in patients with chronic kidney disease, including RTR and hemodialysis patients, indicating that OPG may be involved in the pathogenesis of uremic vascular calcification (10) . Because osteoporosis and vascular disease commonly coexist, it has been speculated that OPG may represent a link between osteoporosis and arterial calcification (11) , which may be of particular interest in organ transplant recipients who are treated with glucocorticoids and cyclosporin A (CsA).
MBL is a serum protein that can activate the complement system independent of antibodies through MBL-associated serine proteases (MASP) (12, 13) . MBL has been suggested to have beneficial effects on atherosclerotic events (14) , and the serum MBL levels were significantly lower among nonsurvivors than survivors in a recently published 3-yr follow-up study of 131 Japanese hemodialysis patients (15) . Furthermore, Fiane et al. (16) demonstrated that MBL deficiency (Ͻ100g/L) was associated with allograft vasculopathy and acute rejection in human heart transplant recipients. In contrast, a recent report showed that higher pretransplantation MBL levels were associated with inferior long-term kidney transplant graft survival (17) .
The primary objectives of our study were to address the prognostic effects of early posttransplantation serum levels of OPG, MBL, MASP-2, and MASP-3 on long-term (8-yr) patient survival, graft survival, and CV death in RTR. In addition, the possible relationship between immunosuppressive therapy and OPG was examined.
Materials and Methods
A total of 173 consecutive patients who received a kidney allograft between February 1995 and June 1996 (18, 19) were evaluated for inclusion. These patients participated in a larger prospective study that was designed to address the prognostic effect of diabetes on survival and CV events (20) . The previous study also included 28 patients with diabetes before transplantation, but frozen sera were not available from these patients. The study was approved by the local ethics committee and was performed in accordance with the Declaration of Helsinki (21) . The study population and the immunosuppressive protocol have been described in detail (18, 19) . Frozen sera that were obtained at baseline, 10 wk (70 Ϯ 6 d) after transplantation, from 172 of 173 patients were available for measurement of high-sensitivity CRP (hsCRP), OPG, MBL, MASP-2, and MASP-3. No patient had diabetes before transplantation, and the majority of patients were white (n ϭ 165). All patients were treated with glucocorticoids, and 97% received CsA. Four patients received tacrolimus, and one patient was treated with mycophenolate (no calcineurin inhibitor).
Baseline CV Risk Factors and Pretransplantation CVD
Glucose tolerance and a number of CV risk factors were examined at baseline (19) . All patients completed a questionnaire that addressed smoking habits and present or pretransplantation symptoms of CVD (e.g., angina pectoris, intermittent claudication). All medical records were reviewed with respect to pretransplantation CVD (myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, significant stenoses as revealed by coronary angiography, aortic aneurysm, or cerebrovascular events). Electrocardiograms were recorded on the day of transplantation. Left ventricular hypertrophy was diagnosed according to the Sokolow-Lyon criteria. In addition, several metabolic risk factors were analyzed and registered prospectively (19) .
Patients with repeated BP values in the sitting or recumbent position above systolic (SBP) 140 mmHg or diastolic (DBP) 90 mmHg and those who were being treated with antihypertensive medication were classified as hypertensive. New-onset posttransplantation diabetes mellitus (PTDM) was diagnosed when fasting serum glucose was Ն7.0 mmol/L or 2-h serum glucose was Ն11.1 mmol/L (oral glucose tolerance test) (22) .
Laboratory Analyses
Blood samples were drawn in the fasting state, 10 wk after transplantation, and immediately after centrifugation and used for determination of glucose, creatinine, and lipids or frozen (Ϫ70°C) for later analyses of hsCRP, OPG, MBL, MASP-2, and MASP-3 (18, 19) . Serum levels of OPG were quantified by enzyme immunoassay using commercially available matched antibodies (R&D Systems, Minneapolis, MN) as described previously (23) . The intra-and interassay coefficients of variation were 3.6 and 10.6%, respectively (23) .
Serum MBL (13) and MASP-2 (24) levels were measured by immunoassays as described previously. Serum MASP-3 was measured by a sandwich-type immunoassay (25) . In brief, a commercially available antibody that reacts against the N-terminal part of MASP-3 was coated in microtiter wells and diluted samples were added. After incubation, the bound MASP-3 was detected by an anti-MASP-3 antibody that reacts with the C-terminal part of MASP-3. Concentrations were estimated from a standard curve made from a standard serum. The intraand interassay variations were Ͻ5 and 10%, respectively. hsCRP was measured as described previously (26) . Briefly, wells were coated overnight with polyclonal rabbit anti-human CRP antibody (A0073; 10 mg/L in sterile PBS). Standard was delipidated, pooled human serum that was enriched in CRP (X 0923; 0.16 to 40 mg/L). Subsequent steps included rabbit anti-human CRP/horseradish peroxidase antibody (P0227, 1:3000) and tetramethylbenzidine as substrate (Zymed Laboratories, San Francisco, CA). Assay buffer was 1% BSA in PBS. All antibodies and standard were from DakoCytomation (Glostrup, Denmark).
Patients were screened for cytomegalovirus (CMV) infection the first 10 wk after transplantation by repeated measurements of CMV pp65 lower matrix protein in EDTA blood samples. The assay for CMV pp65 antigen was performed as described previously (27) . CMV infection was diagnosed in patients who had at least one positive CMV pp65 antigenemia test (Ն1 CMV pp65-positive cells per 100,000 leukocytes) (27, 28) .
Long-Term Outcomes: Definitions and Assessment
End point data were collected from the Norwegian Renal Registry as reported recently (20) . The registry includes all Norwegian patients who are on renal replacement therapy and is based on annual reports that include detailed information on medication, laboratory tests, immunosuppressive therapy, graft survival, and CV complications. When a patient dies, the event is reported immediately. Death was categorized according to the ERA-EDTA causes of death codes i.e. CV; cardiac (11 to 18) or vascular (21 to 28), infection (31 to 42), or malignancy (66 to 67) (http://www.show.scot.nhs.uk/srr/ ERA_EDTA/ERA_EDTA_PRD_Codes_Deaths.pdf).
Statistical Analyses
Data are presented as means and SD or medians and interquartile range. Mann-Whitney test (nonparametric) was used for comparisons of baseline levels of OPG, MBL, MASP-2, and MASP-3 between groups of patients. Proportions were analyzed by Pearson 2 test or Fisher exact test as appropriate. Univariate and multiple Cox proportional hazards regression models were used to analyze the effects of the potential explanatory variables on the cumulative incidence of patient survival, graft survival, and CV death, respectively. In the univariate Cox regression analyses, patients with baseline levels of OPG, MBL, MASP-2, and MASP-3 above median or the 75th percentile were compared with those with baseline levels below median or within the 75th percentile (reference groups), respectively. In the multiple Cox regression analyses, patients with baseline levels of OPG above the 75th percentile were compared with those with lower OPG levels. We used Kaplan-Meier plots and log-rank tests to illustrate the effects of various levels of OPG on death from any cause and CVD. Associations between potential independent variables and OPG as dependent variable were assessed by linear regression. Skewly distributed parameters were log-transformed before statistical analyses. Variables that showed a significant bivariate association with OPG were included in a multiple linear regression analysis, and their relative influence on OPG (dependent) levels was addressed. The analyses were implemented using SPSS 12.0 (SPSS, Inc., Chicago, IL). We report two-tailed P values and used a 5% level of statistical significance.
Results

Baseline Characteristics
A brief summary of baseline characteristics is given in Table  1 (18, 19) .
Death from Any Cause or CVD
A total of 40 (23%) patients died, and 18 deaths were related to CVD. Nonsurvivors and patients who died from CVD had on average significantly higher levels of OPG than survivors and patients who did not die from CVD, respectively (Table 2) . A subanalysis that compared patients who died from CVD with survivors (n ϭ 132) revealed similar results (data not shown). Baseline serum concentrations of MBL, MASP-2, and MASP-3 did not differ significantly between the groups of patients. The Kaplan-Meier estimates of patient survival and CV death according to high (fourth quartile) versus low (first through third quartiles) OPG levels are illustrated in Figure 1 .
Unadjusted hazard ratios (HR) of the adverse outcomes according to various serum concentrations of OPG, MBL, MASP-2, and MASP-3 are given in Table 3 , confirming the strong association between OPG levels and death from any cause or CVD. Patients with serum OPG levels in the upper quartile (HiOPG) had an approximately six-and 10-fold increased risk for death and CV death, respectively, as compared with patients with lower serum OPG concentrations. In contrast, serum levels of MBL, MASP-2, and MASP-3 were not significantly associated with adverse outcomes.
Independent Prognostic Value of HiOPG on All-Cause Mortality (Multiple Cox Regression)
Forward conditional proportional hazards regression analyses were conducted to include all variables that were significantly associated with all-cause mortality in the univariate analyses: OPG, age, creatinine clearance, pretransplantation CVD, hsCRP (quartiles), and CMV infection. HiOPG remained significantly associated with a six-fold increased all-cause mortality risk (HR 6.0; 95% confidence interval [CI] 3.1 to 11.6; P Ͻ 0.001) in the multiple Cox regression model. In addition, CMV infection was retained as an independent predictor of death in this model (HR 2.7; 95% CI 1.2 to 6.1; P ϭ 0.020). No significant interactions between hsCRP and OPG or between creatinine clearance and OPG were observed (data not shown). Backward proportional hazards regression analysis yielded similar results (data not shown). In addition, patients with HiOPG had a significantly higher risk for death even after adjustments for age, creatinine clearance, hsCRP, and CMV infection (Table 4) .
Independent Prognostic Value of HiOPG on CV Death (Multiple Cox Regression)
Forward conditional proportional hazards regression analyses also were conducted to include all variables that were significantly associated with CV death in the univariate analyses: OPG, age, gender, pretransplantation CVD, left ventricular hypertrophy, HDL cholesterol and PTD. HiOPG remained significantly associated with an eight-fold increased risk for CV death (HR 8.2; 95% CI 2.5 to 26.4; P Ͻ 0.001) in the multiple Cox regression model. Moreover, pretransplantation CVD (HR 6.1; 95% CI 2.2 to 16.7; P Ͻ 0.001) and left ventricular hypertrophy (HR 2.8; 95% CI 1.0 to 7.8; P ϭ 0.046) were retained as independent predictors of CV death in the model. In addition, HiOPG levels predicted CV death also after adjustment for hsCRP (HR 10.1; 95% CI 3.5 to 29.5; P Ͻ 0.001).
Risk Factors Associated with OPG
To examine further the association between relevant baseline risk factors and OPG, we conducted univariate and multiple linear regression analyses (Table 5 ). Univariate regression analyses revealed strong correlations between OPG (ln, dependent) and age, creatinine clearance, hsCRP, and daily dose of CsA (Table 5 ). It is interesting that total steroid dose, PTD, CMV infection, pretransplantation CVD, and nephrosclerosis were associated with higher OPG concentrations in the univariate analyses. No statistically significant relationships between hypertension and OPG or between dialysis vintage and OPG were revealed (data not shown).
Multiple linear regression analysis revealed that age, creatinine clearance, and hsCRP all were independently associated with OPG (Table 5 ). This model explained 42% of the variation in ln OPG. Age, hsCRP, and creatinine clearance explained 10, 8, and 5% of the variance in OPG, respectively, independent of other variables in the model (squared partial correlations). Early posttransplantation OPG levels did not differ significantly between patients who received pretransplantation dialysis (n ϭ 124) and those with preemptive transplants (n ϭ 48) or between patients who had received a previous transplant and those who were receiving their first allograft (data not shown).
Graft Survival
The mean death-censored graft survival was 96 mo, and 21 (12%) patients lost their graft during the follow-up period. No statistically significant relationships were found between baseline levels of OPG, MBL, MASP-2, or MASP-3 on long-term graft survival (data not shown).
Subanalyses of Patients Who Received CsA (n ϭ 167)
All statistical analyses were repeated after exclusion of patients who did not receive CsA (n ϭ 5). The results from these analyses essentially were identical with the results given above (data not shown).
Discussion
The prognostic long-term effects of specific serum proteins that were measured early after transplantation were addressed in this study. Baseline OPG was shown to be a strong and independent predictor of long-term (7 to 9 yr) death from any cause and CVD in RTR.
Comparison with Other Studies
To our knowledge, this is the first study to demonstrate an independent association between OPG levels and survival in RTR. Multiple Cox regression analysis revealed that HiOPG independently predicted a four-to eight-fold increased risk for death from any cause or CVD, respectively. Although the relative risk for death seems higher than reported by others (9, 29) , it is important to acknowledge the relatively wide CI presented in our study. In addition, direct comparisons of HR between this and previous studies might be inappropriate because of important differences in analysis and presentation of data. First, in a study of elderly women (29) , the estimated increased risk was given as odds ratio (1.4) per SD increase in OPG levels.
Second, in a study of hemodialysis patients (9) , the population was divided in tertiles according to OPG levels, and the second tertile was chosen as reference group (HR 1). We compared patients in the fourth quartile with those in the lower three quartiles, although similar results were revealed when tertiles were implemented in the statistical analysis (data not shown). In view of this, our results seem to be in concert with previous studies (7) (8) (9) 29) . Although a recent study suggested that pretransplantation MBL levels may predict long-term graft survival (17), we could not demonstrate any significant effect of early posttransplantation serum MBL on 8-yr graft survival.
Potential Predictors of OPG
Two relatively small studies demonstrated a decline in OPG levels after renal transplantation (10, 30) . This might be explained by improved renal function as suggested by the inverse association between creatinine clearance and OPG in this study. Furthermore, in vitro studies in various cell types and shortterm in vivo studies have shown that glucocorticoids decrease OPG expression (31,32). However, in our study, univariate linear regression analysis revealed a positive relationship between total steroid dose and serum OPG levels, more in line with studies in patients who had long-standing Cushing's syndrome and showed increased circulating OPG (23) . Conversely, daily dose of CsA was inversely correlated with OPG, supporting one previous study that showed that CsA decreased OPG mRNA and protein production in human stromal and coronary smooth muscle cells in a dose-dependent manner (33) . However, these associations lost significance in the multiple linear regression model, and further study is necessary to explore how immunosuppressive drugs may modulate OPG.
It is interesting that our study revealed a strong and independent correlation between hsCRP and OPG. This is in accordance with findings from the general population (7, 34) but in contrast with a recent French study in hemodialysis patients (9) . Although CRP has been associated with increased risk for death and CV events in RTR (4 -6), hsCRP did not attenuate the association between OPG and outcomes in our study. Importantly, the cross-sectional design of the baseline study makes it difficult to discern any causal relationship between hsCRP and OPG. Finally, in contrast with the French study that reported no significant association between elevated OPG levels and mortality in patients with CRP levels Ͻ12.5 mg/L (9), we did not find any significant interaction between hsCRP and OPG. 
Possible Mechanisms to Explain the Negative Prognostic Effects of OPG
Coronary artery calcification (CAC) as diagnosed by computed tomography, is an independent predictor of future cardiac events in the general population, and the prevalence of CAC is particularly high in patients with chronic kidney disease (10, 35, 36) . Importantly, OPG has been demonstrated to be independently associated with CAC and aortic calcification in hemodialysis patients (10, 35, 37) and RTR (10) . In view of this, the impact of OPG on cardiac death or nonfatal acute myocardial infarction also was addressed in our study. The results were similar to those reported for CV death (data not shown).
SBP was reported recently to be associated with OPG in patients with type 1 diabetes (38). We did not find any statistically significant association between hypertension (yes/no) and OPG, however. Although SBP and DBP were not registered prospectively in the baseline study, we succeeded in providing valid BP measurements from a previous randomized, controlled study at our center (39) or in patient records from the majority (87%) of patients. It is interesting that univariate analyses revealed that both SBP and pulse pressure were significantly associated with serum OPG levels (r ϭ 0.16 and 0.24, P ϭ 0.048 and 0.004, respectively), whereas DBP were not significantly associated with OPG (r ϭ 0.07, P ϭ 0.431). However, after adding either pulse pressure or SBP to a multiple linear regression analysis that included the variables that are shown in Table 5 , the relationship between these parameters and OPG lost statistical significance (data not shown).
Because OPG is produced by many cell types, including endothelial and smooth muscle cells, cardiomyocytes, and other cells that are present in the vasculature, such as fibroblasts, it is hard to determine any specific source of the increased circulating OPG found in this study. Most likely, serum OPG is a reflection of many sources, including cells that line the vasculature as major depots. More interesting perhaps is the role of increased serum OPG. In bone biology, OPG is observed as a positive determinant of bone mass because it may block osteoclastic activation, and the age-related increase in OPG has been identified as a compensatory response (40, 41) . Its role in the vasculature is less recognized. However, increased arterial OPG has been observed in diabetes, possibly related to development of vascular calcification (42) . Furthermore, endothelial dysfunction with death of endothelial cells is viewed as an early event in vascular disease development, and OPG has been related to endothelial cell survival (43) , apoptosis (44) , and modulation of the endothelial inflammatory response (45). Therefore, future studies are warranted to penetrate the mechanisms and consequence of elevated OPG in relation to CV mortality in these patients.
No Significant Adverse Prognostic Effects of MBL, MASP-2, and MASP-3
MBL, MASP-2, and MASP-3 were not associated with 8-yr survival or CV death. This finding is supported to some extent by the results of a large Danish population-based follow-up study (8 to 24 yr) of approximately 10,000 adults that showed that MBL deficiency is not a major risk factor for morbidity and death (46) . However, our results are in contrast with the Japanese 3-yr follow-up study of hemodialysis patients that showed lower serum MBL concentrations in nonsurvivors (15) . To our knowledge, no other study has addressed the possible associations between MBL, MASP-2, and MASP-3 and CV end points in RTR, and further studies obviously are needed.
Limitations
Neither of the specific serum proteins that were addressed in our study predicted 8-yr graft survival. Although this lack of association might be correct, a larger number of patients prob- ably are necessary to ensure sufficient power to reveal any possible effects of MBL or OPG on graft loss.
The possible relationships between serum calcium, phosphate, parathyroid hormone, and OPG were not addressed in the original study. However, laboratory results of calcium and phosphate were available from the majority (88%) of patients, whereas parathyroid was available only from the last 57 consecutive patients who were included in the study. No significant correlations between any of these parameters and OPG were revealed (data not shown). Furthermore, no significant relationship was found between serum calcium, phosphate, and long-term outcomes (data not shown).
The majority of patients were white and treated with a combination of glucocorticoids and CsA, and the results may not be extrapolated directly to nonwhite patient populations or patients who are receiving other immunosuppressive drugs, including tacrolimus, mammalian target of rapamycin inhibitors, and steroid-free regimens. However, taking into account the possible inhibitory effects of glucocorticoids and CsA on OPG synthesis, the predictive effect of raised OPG levels on mortality actually may have been underestimated in our study. Conversely, if increasing serum OPG is a beneficial compensatory mechanism to an ongoing atherosclerotic process, then the inhibitory effect of immunosuppressive drugs actually may have counteracted this positive response. In view of the relatively low numbers of patients and clinical events, our results need verification and should be interpreted with care.
Conclusions
Early measured posttransplantation serum OPG is an independent predictor of death from any cause or CVD in white RTR. a Univariate proportional hazards regression analyses (Cox regression). The patients with values Ͻ75% and median served as reference groups (hazard ratio ͓HR͔ 1) for patients with values Ͼ75% and median, respectively. The group of patients with MBL Ͼ100 g/L served as reference (HR 1) versus the group of patients with MBL Ͻ100 g/L. Nonsurvivors (n ϭ 40), survivors (n ϭ 132), death from CV disease (18) , no death from CV disease (n ϭ 154). CI, confidence interval. 
